Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

- PMLiVE

Data regulations impeding AI use in drug research

Lack of data specialists another concern

- PMLiVE

Spinraza managed access deal in England breaks deadlock for Biogen

Patient groups remain wary, call for changes to NICE

- PMLiVE

Rare disease trials Q&A

By Gretchen Goller and Valerie Legrand

- PMLiVE

Is anybody listening?

Chris Ross explores how pharma can – indeed must – end its long history of anti-social behaviour

Lucid Group strengthens its scientific leadership and client service team with two new hires

Two Lucid Group companies, Vivid and Leading Edge, welcome new talent to their teams.Eve Raebel joins Vivid as a medical writer. Eva has 2 years’ experience as a scientific writer...

Lucid Group Communications Limited

- PMLiVE

Crossing the digital divide between big pharma and real-world patients

Can pharma harness the digital world?

- PMLiVE

Bluebird and Alexion veterans launch cell and gene venture ElevateBio

'Basecamp' will provide expertise and labs to launch multiple firms

Eli Lilly HQ

Lilly scores FDA okay for Cyramza in liver cancer

Approved as second line treatment after Bayer’s Nexavar

- PMLiVE

Grail’s multi-cancer blood test gets FDA breakthrough status

Could detect multiple cancers from single blood sample

- PMLiVE

Pfizer’s alliance with Sosei Heptares bears first fruit

Partners focusing on GPCR-targeting drugs

Porterhouse Medical Advisory Group

Deploying clinical experience and insight to gain maximum impact

Introducing the Porterhouse Medical Advisory Group (MAG)

Porterhouse Medical Group

- PMLiVE

The trials and tribulations of rare opportunities

Those hoping to follow where Humira, Soliris and Fabrazyme led should be prepared for clinical development to be complex

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links